Race Oncology Limited (ASX:RAC)

Race Oncology Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Other Revenue	5.25	4	3.13	0.71	0.39	0.16
Revenue	5.25	4	3.13	0.71	0.39	0.16
Revenue Growth (YoY)	-9.65%	27.73%	342.83%	82.71%	143.07%	-30.25%
Cost of Revenue	1.15	2.61	2.03	0.99	0.62	0.44
Gross Profit	4.11	1.39	1.11	-0.28	-0.23	-0.28
Selling, General & Admin	3.38	3.79	3.04	4.33	3.34	1.95
Research & Development	7.31	10.98	7.6	5.83	2.2	1.28
Other Operating Expenses	0.76	0.82	0.66	0.48	0.31	0.14
Operating Expenses	12.33	15.87	11.58	10.92	6.13	3.65
Operating Income	-8.22	-14.48	-10.48	-11.2	-6.36	-3.93
Interest & Investment Income	0.73	0.83	0.59	0.05	0.02	0.01
Other Non Operating Income (Expenses)	-0.16	-0.17	-0.04	-0.05	-0.04	-0.01
EBT Excluding Unusual Items	-7.65	-13.82	-9.92	-11.2	-6.38	-3.93
Other Unusual Items	-	-	-	-	0.04	0.08
Pretax Income	-7.65	-13.82	-9.92	-11.2	-6.34	-3.85
Net Income	-7.65	-13.82	-9.92	-11.2	-6.34	-3.85
Net Income to Common	-7.65	-13.82	-9.92	-11.2	-6.34	-3.85
Shares Outstanding (Basic)	169	165	161	153	131	107
Shares Outstanding (Diluted)	169	165	161	153	131	107
Shares Change (YoY)	4.44%	2.35%	4.83%	17.06%	22.86%	33.50%
EPS (Basic)	-0.05	-0.08	-0.06	-0.07	-0.05	-0.04
EPS (Diluted)	-0.05	-0.08	-0.06	-0.07	-0.05	-0.04
Gross Margin	78.13%	34.72%	35.35%	-39.91%	-60.07%	-178.09%
Operating Margin	-156.53%	-361.80%	-334.22%	-1582.76%	-1641.48%	-2466.26%
Profit Margin	-145.66%	-345.18%	-316.60%	-1582.63%	-1636.70%	-2413.22%
EBITDA	-7.94	-14.2	-10.19	-10.92	-6.08	-3.65
D&A For EBITDA	0.28	0.28	0.28	0.28	0.28	0.28
EBIT	-8.22	-14.48	-10.48	-11.2	-6.36	-3.93
Revenue as Reported	-	-	-	-	-	0.26

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.